These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 1887166)
21. Engineering bacterial toxin for the development of new vaccine against pertussis. Bartoloni A; Pizza M; Gross R; Perugini M; Arico B; Domenighini M; Rappuoli R Tokai J Exp Clin Med; 1988; 13 Suppl():217-22. PubMed ID: 2483870 [TBL] [Abstract][Full Text] [Related]
22. Bordetella parapertussis infections. Mastrantonio P; Giuliano M; Stefanelli P; Sofia T; De Marzi L; Tarabini G; Quarto M; Moiraghi A Dev Biol Stand; 1997; 89():255-9. PubMed ID: 9272358 [TBL] [Abstract][Full Text] [Related]
23. Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004. Advani A; Donnelly D; Gustafsson L; Hallander HO APMIS; 2007 Apr; 115(4):299-310. PubMed ID: 17504296 [TBL] [Abstract][Full Text] [Related]
24. Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children. Sato Y; Sato H Dev Biol Stand; 1985; 61():367-72. PubMed ID: 3835079 [TBL] [Abstract][Full Text] [Related]
25. Comparative analysis of a Bordetella pertussis patient isolated strain and classical strains used in the pertussis vaccine. Pereira A; Pereira AS; Moreira-Filho CA; Bando SY; Tambourgi DV Vaccine; 2005 Jul; 23(34):4353-8. PubMed ID: 16005744 [TBL] [Abstract][Full Text] [Related]
26. The Bordetella type III secretion system: its application to vaccine development. Abe A; Nagamatsu K; Watanabe M Microbiol Immunol; 2008 Feb; 52(2):128-33. PubMed ID: 18380810 [TBL] [Abstract][Full Text] [Related]
27. Genetic studies of the molecular basis of whooping cough. Weiss AA; Hewlett EL; Myers GA; Falkow S Dev Biol Stand; 1985; 61():11-9. PubMed ID: 2872097 [TBL] [Abstract][Full Text] [Related]
28. Pertussis: a matter of immune modulation. de Gouw D; Diavatopoulos DA; Bootsma HJ; Hermans PW; Mooi FR FEMS Microbiol Rev; 2011 May; 35(3):441-74. PubMed ID: 21204863 [TBL] [Abstract][Full Text] [Related]
29. The virulence factors of Bordetella pertussis: talented modulators of host immune response. Fedele G; Bianco M; Ausiello CM Arch Immunol Ther Exp (Warsz); 2013 Dec; 61(6):445-57. PubMed ID: 23955529 [TBL] [Abstract][Full Text] [Related]
30. Bordetella pertussis: new concepts in pathogenesis and treatment. Carbonetti NH Curr Opin Infect Dis; 2016 Jun; 29(3):287-94. PubMed ID: 26906206 [TBL] [Abstract][Full Text] [Related]
31. Vaccine-driven virulence evolution: consequences of unbalanced reductions in mortality and transmission and implications for pertussis vaccines. Miller IF; Metcalf CJ J R Soc Interface; 2019 Dec; 16(161):20190642. PubMed ID: 31822219 [TBL] [Abstract][Full Text] [Related]
38. What is infectiveness and how is it involved in infection and immunity? Pirofski LA; Casadevall A BMC Immunol; 2015 Mar; 16():13. PubMed ID: 25887484 [TBL] [Abstract][Full Text] [Related]
39. Pertussis vaccine. Br Med J (Clin Res Ed); 1981 Jun; 282(6281):2051-2. PubMed ID: 6788187 [No Abstract] [Full Text] [Related]